Bone Diseases  >>  risedronate delayed-release  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
risedronate delayed-release / Generic mfg.
NCT00846196: A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

Completed
3
538
US
risedronate DR (Phase III clinical supply), Phase III clinical supply, risedronate 35 mg DR (Commercial Tablet), Commercial Tablet
Warner Chilcott, Sanofi
Osteoporosis
05/09
05/09
NCT00541658 / 2007-001521-98: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Completed
3
923
US, Canada, Europe, RoW
risedronate, IRBB, DRFB, DRBB
Warner Chilcott
Postmenopausal Osteoporosis
04/10
04/10

Download Options